MK-677 (Ibutamoren) International Purchase Legalities: What You Need to Know in 2026

What MK-677 (Ibutamoren) Actually Is

MK-677 is a non-peptide, orally active ghrelin receptor agonist that stimulates pulsatile growth hormone (GH) secretion and raises IGF-1 levels. It was originally developed by Merck & Co. And later studied by Novo Nordisk and Eli Lilly for conditions including growth hormone deficiency, muscle wasting, and osteoporosis. No pharmaceutical company has carried it to FDA approval.

Because it mimics ghrelin at the GHSR-1a receptor, it produces GH pulses without suppressing the hypothalamic-pituitary axis in the same way that exogenous GH does. A 2-year randomized controlled trial (N=65) published in the Journal of Clinical Endocrinology and Metabolism found that oral MK-677 25 mg/day significantly increased GH and IGF-1 levels but also raised fasting glucose by a mean of 0.3 mmol/L compared with placebo, P<0.05. [1]

Mechanism Compared to Exogenous GH

Exogenous recombinant human growth hormone (somatropin) is injected, suppresses endogenous GH pulsatility over time, and is FDA-approved for specific indications. MK-677 is taken orally and preserves pulsatile GH release. That pharmacological distinction is scientifically interesting, but it does not change the compound's regulatory status: the FDA classifies any compound intended for human therapeutic use as a drug, regardless of how it is administered. The FDA's own guidance on unapproved drugs confirms that marketing a product for human use without an approved New Drug Application (NDA) violates the Federal Food, Drug, and Cosmetic Act. [2]

Research-Grade vs. Pharmaceutical-Grade

Nearly all MK-677 sold today is "research-grade," meaning it is manufactured in facilities that are not subject to FDA Current Good Manufacturing Practice (cGMP) requirements for drug products. Research-grade compounds may be mislabeled, under-dosed, or contaminated. A 2023 analysis of 44 compounds sold as SARMs or growth hormone secretagogues found that fewer than 30% matched their label claims for purity and concentration, with some samples containing unlisted pharmaceutical compounds. This was consistent with prior FDA warnings about SARM-containing products. [3]

U.S. Regulatory Status and Import Rules

MK-677 is not a controlled substance under the Controlled Substances Act. That single fact is frequently misread as "legal to buy." The more accurate picture is more complicated.

What "Not Scheduled" Actually Means

The DEA's scheduling system governs substances with abuse potential. MK-677 has not been added to Schedules I through V, so possession alone is not a federal criminal matter in the way that, say, possession of anabolic steroids (Schedule III) would be. The FDA's authority, however, is different. The FDA regulates drugs, and MK-677 qualifies as a drug under 21 U.S.C. § 321(g)(1) if it is intended for human use. Selling it with therapeutic claims or importing it for personal therapeutic use can constitute introducing an unapproved new drug into interstate commerce, which is a prohibited act under 21 U.S.C. § 331(d). The FDA's import alert system (Import Alert 54-15) has already been used to detain shipments of SARMs and related compounds. [4]

Personal Importation Policy

The FDA has a well-known personal-importation policy that tolerates, on a case-by-case enforcement basis, individuals importing up to a 3-month supply of a foreign-approved drug for personal use, provided there is no commercialization, the drug poses no unreasonable safety risk, and the individual provides written confirmation that the product is for personal use. MK-677 does not meet the key prerequisite: it is not approved for human use in any major jurisdiction. Packages are routinely seized at U.S. Customs without criminal charges, but seizure letters are issued and repeat offenses draw increased scrutiny. The FDA's personal importation policy guidance document outlines these requirements in full. [5]

State-Level Variation

A handful of U.S. States have enacted their own analogue or designer-drug statutes that could apply to MK-677 depending on how the compound is characterized. No state had explicitly scheduled MK-677 by name as of early 2026, but practitioners in those states should review their state pharmacy board guidance before advising patients.

International Regulatory Status by Country

Regulatory categorization of MK-677 varies more than most online sources acknowledge. The table below summarizes the 2026 position across major jurisdictions.

United Kingdom

Under the Human Medicines Regulations 2012, any substance presented as having medicinal properties requires a marketing authorization. MK-677 has none. The Medicines and Healthcare products Regulatory Agency (MHRA) treats importation of unlicensed medicinal products for personal use as a criminal offense if quantities exceed a reasonable personal supply, typically interpreted as one month. The MHRA's position on unlicensed medicines is consistent with broader EU precedent. [6]

Canada

Health Canada classifies MK-677 as a Schedule F prescription drug. This means it may only be sold by a licensed pharmacist on the basis of a valid prescription. Importation for personal use requires prior authorization, which Health Canada rarely grants for non-approved compounds. Customs seizures are common. Health Canada's drug scheduling framework is publicly accessible through its online database. [7]

Australia

The Therapeutic Goods Administration (TGA) lists ibutamoren as a Schedule 4 substance (prescription only) in the Poisons Standard. Importation of Schedule 4 substances without a valid Australian prescription and TGA import permit is prohibited. The TGA's Poisons Standard scheduling is updated twice yearly. Referencing the TGA falls outside the allow-list for inline hyperlinks, so note that TGA documentation should be independently verified. The key enforcement reality: Australian Border Force has seized multiple shipments of ibutamoren since 2022. [8]

European Union

No EU member state has granted a marketing authorization for MK-677. Under Directive 2001/83/EC, importing an unauthorized medicinal product is prohibited. Enforcement intensity varies by member state: Germany (§ 95 AMG) and France (Code de la santé publique) both carry criminal penalties, while enforcement in some Eastern European states is lighter in practice. The European Medicines Agency's public registry confirms no authorized products containing ibutamoren exist. [9]

Japan and South Korea

Both countries classify compounds intended for human use under their pharmaceutical affairs laws and treat MK-677 as an unapproved drug. South Korea's Ministry of Food and Drug Safety has issued public advisories about GH secretagogues, citing cardiovascular and metabolic risks.

Why People Seek MK-677 Internationally

The honest answer is cost and access. A 30-day supply of research-grade MK-677 from a domestic U.S. Supplier costs roughly USD $40, $80. Similar products sourced from Chinese or Indian chemical manufacturers and shipped directly may cost $10, $25 per month before shipping. The difference narrows considerably once you account for shipping costs, customs risk, and the absence of any third-party certificate of analysis (CoA). Contaminant risks in unregulated GH-secretagogue products are not hypothetical. A 2021 case series described elevated liver enzymes in four bodybuilders who had used SARMs purchased online, at least two of whom had used MK-677 concurrently. [10]

Discount Strategies That Avoid Import Risk

Several cost-reduction approaches do not require crossing international shipping lines.

Subscription and auto-ship programs. Some domestic research suppliers offer 15 to 25% discounts on auto-ship orders. The tradeoff is commitment to a recurring purchase. Given that long-term safety data for MK-677 in humans beyond 24 months remain limited, locking into a lengthy auto-ship contract deserves scrutiny.

Bulk quantity discounts. Purchasing a larger bottle (60 mL or 90 mL vs. 30 mL) typically reduces per-mL cost by 20 to 30%. This approach keeps sourcing domestic and eliminates customs risk.

Coupon aggregators and institutional pricing. Several legitimate U.S. Research suppliers post active discount codes through third-party coupon sites. These discounts are real and are often 10 to 20% off listed prices.

None of these strategies change the underlying regulatory status of the compound. Cost reduction is not a reason to treat MK-677 as safe or legally cleared for human use.

Clinical Evidence Base: What the Trials Actually Show

Understanding the trial data matters for any discussion of why someone might seek MK-677 and what risks they accept in doing so.

Growth Hormone and IGF-1 Effects

The most frequently cited trial is a 24-month double-blind RCT (N=65, mean age 64 to 81) published in the Journal of Clinical Endocrinology and Metabolism. Participants received oral MK-677 25 mg/day or placebo. GH pulse amplitude increased significantly in the MK-677 group, and mean IGF-1 rose by approximately 39% from baseline vs. A 3.7% rise in the placebo group. Fat-free mass increased by 1.1 kg in the treatment arm. Importantly, congestive heart failure was reported in 6 of 32 MK-677-treated patients vs. 1 of 33 placebo patients, P<0.05, raising a signal for cardiovascular risk in older populations. [1]

Glucose and Insulin Resistance

MK-677 consistently increases fasting insulin and reduces insulin sensitivity in human trials. This effect is dose-dependent and appears within 2 weeks of initiating 25 mg/day. For individuals with pre-diabetes or metabolic syndrome, this signal is clinically meaningful. A Phase II crossover study (N=24) reported a 17% increase in fasting insulin after 14 days of MK-677 25 mg compared with placebo. [11]

Muscle and Bone Outcomes

A separate randomized trial in 123 hip-fracture patients found that MK-677 improved functional measures and reduced the number of falls at 6 months vs. Placebo, but the primary endpoint of bone mineral density did not reach statistical significance. That study was published in the Journal of the American Geriatrics Society and is accessible via PubMed. [12]

What No Trial Has Established

No published RCT has shown that MK-677 reduces all-cause mortality, cardiovascular mortality, or produces durable body composition benefits beyond 24 months. No trial has been conducted in healthy adults under 50 seeking body composition or anti-aging outcomes, which represents the dominant current use case. Extrapolating from elderly hip-fracture data to a 35-year-old seeking muscle gain involves substantial assumptions. The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency in adults does not mention MK-677 as an evidence-based treatment option. [13]

Safety Signals That Affect the Risk-Benefit Calculation

MK-677 is not without documented adverse effects. Short-term trials identify the following patterns:

• Increased appetite. Ghrelin receptor agonism stimulates appetite in virtually all subjects. Mean caloric intake increases by an estimated 8 to 10% in controlled settings.
• Water retention and edema. Peripheral edema occurs in 15 to 20% of subjects at 25 mg/day in published trials. This can be confused with muscle gain in unmonitored use.
• Elevated fasting glucose. As noted above, this signal is consistent and reproduced across multiple trials. People with a family history of type 2 diabetes or a baseline HbA1c above 5.6% face elevated risk. The American Diabetes Association's 2024 Standards of Care note that drug-induced hyperglycemia should prompt investigation of the offending agent and lifestyle modification before pharmacological intervention. [14]
• Increased cortisol. A modest rise in morning cortisol has been reported, with uncertain clinical significance at standard doses.
• Lethargy and somnolence. These are common in the first 2 to 4 weeks of use and may be dose-dependent. Splitting the dose morning and evening does not fully resolve this in most users.

A 2020 systematic review of growth hormone secretagogues in adults found that adverse event reporting in most trials was incomplete, limiting the ability to draw firm conclusions about long-term safety profiles. [15]

HSA/FSA Eligibility for MK-677

MK-677 is not eligible for payment through a Health Savings Account (HSA) or Flexible Spending Account (FSA). Eligibility under IRS Publication 502 requires that the expense be for a "medical care" service or product. The IRS defines a medicine or drug as one that requires a prescription or is available over-the-counter for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. MK-677 meets none of those criteria in the U.S. Context: it lacks FDA approval, cannot be legally prescribed, and is not marketed as an OTC drug. The IRS's CARES Act expansion of eligible OTC products in 2020 did not extend to unapproved research compounds. [16]

Any supplier or telehealth platform claiming that MK-677 purchases are HSA/FSA-eligible is making an incorrect claim. Submitting such an expense could constitute an improper distribution from your HSA, triggering a 20% penalty plus income tax on the distribution amount under IRS rules.

What a Physician-Supervised Alternative Looks Like

For individuals seeking GH axis support through a legal, physician-supervised route, several FDA-approved or compounding-pharmacy-dispensed options exist. Sermorelin (a GHRH analogue) is available from licensed compounding pharmacies under a physician's prescription. Tesamorelin is FDA-approved for HIV-associated lipodystrophy under the brand name Egrifta SV. Recombinant human GH (somatropin) is FDA-approved for adult GHD when diagnosed by appropriate stimulation testing. The Endocrine Society's 2019 guidelines specify that adult GHD diagnosis requires a peak GH response below 5 mcg/L on an insulin tolerance test or glucagon stimulation test in most patients. [13]

None of these options involves importing an unapproved compound from overseas. All of them involve documented clinical indication, monitoring labs, and prescriber accountability.

Practical Risk Summary for Patients Considering International Purchase

Purchasing MK-677 from an overseas supplier involves at least four distinct risk categories:

1. Legal risk. Package seizure is common. Criminal prosecution is rare for individual importers in the U.S., but is not zero, and is meaningfully higher in the UK, Canada, Australia, and Germany.
2. Product quality risk. No cGMP manufacturing standard applies. Mislabeling, contamination, and incorrect dosing are documented in independent testing of similar compounds.
3. Health risk. Elevated glucose, edema, and the unanswered cardiovascular signal from the elderly trial cohort are reasons for caution, particularly in the absence of physician monitoring.
4. Financial risk. No recourse exists if a product is seized, mislabeled, or causes harm. HSA/FSA reimbursement is not available.

The lowest-risk path for anyone with a genuine clinical interest in GH axis optimization is a formal evaluation by a board-certified endocrinologist, including IGF-1 and GH stimulation testing. The Endocrine Society's member-find tool can locate board-certified endocrinologists in the U.S. [17]